MASH

Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH).

liver
Biotech

Madrigal pens $2B deal for CSPC's GLP-1, eyes Rezdiffra pairing

Madrigal is paying $120 million upfront for a preclinical GLP-1 agonist the biopharma plans to pair with its fatty liver disease med Rezdiffra.
James Waldron Jul 30, 2025 7:35am
Fingers crossed

Boehringer 'crossing fingers' ahead of 2 key FDA approvals

Jul 24, 2025 3:00am
Liver

Altimmune stock sinks on mixed ph. 2 MASH results for GLP-1 drug

Jun 26, 2025 8:41am
liver transplant

Rivus weight loss drug shows MASH win, muscle-sparing potential

Jun 24, 2025 10:07am
liver

South Korean biotech's GLP-1 scores MASH win, reduces weight

Jun 16, 2025 7:22am
GlaxoSmithKline

GSK pays $1.2B upfront for Boston's lead liver disease drug

May 14, 2025 2:53am